Increased risk of migraine in patients with psoriasis: A Danish nationwide cohort study - 15/10/15
Abstract |
Background |
Psoriasis and migraine are common conditions with potential overlap of pathophysiological mechanisms. Both these diseases have been associated with increased cardiovascular risk but little is known about their interplay.
Objective |
We sought to investigate the link between psoriasis, and the risk of new-onset migraine, in a nationwide cohort of the Danish population.
Methods |
Data on all Danish citizens aged 18 years or older from January 1, 1997, to December 31, 2011, were linked at individual-level in nationwide registers. Incidence rates per 1000 person-years were calculated and crude and adjusted incidence rate ratios were estimated by Poisson regression models.
Results |
The study comprised a total of 5,379,859 individuals, including 53,006 and 6831 patients with mild and severe psoriasis, respectively, and 6243 patients with psoriatic arthritis. Fully adjusted incidence rate ratios for migraine were 1.37 (95% confidence interval 1.30-1.45), 1.55 (95% confidence interval 1.29-1.86), and 1.92 (95% confidence interval 1.65-2.22) for mild psoriasis, severe psoriasis, and psoriatic arthritis, respectively. Stratification for sex revealed increased risk of migraine in both male and female patients.
Limitations |
We were unable to distinguish between subtypes of migraine, eg, migraine with and without aura.
Conclusions |
Psoriasis was associated with a disease severity-dependent increased risk of migraine independent of measured confounders. Further studies are warranted to determine the effects of antipsoriatic treatment on this association, and whether migraine modifies the psoriasis-associated risk of cardiovascular disease.
Le texte complet de cet article est disponible en PDF.Key words : epidemiology, headache, inflammation, migraine, psoriasis
Abbreviations used : ATC, CI, ICD-8, ICD-10, IRR
Plan
Supported by a grant from Pfizer. |
|
Disclosure: Dr Hansen is supported by a grant from the LEO Foundation. Dr Gislason is supported by an unrestricted research scholarship from the Novo Nordisk Foundation. Drs Egeberg and Mallbris are currently employed by Pfizer and Eli Lilly and Company, respectively. Dr Skov has received consultancy and/or speaker honoraria from Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, and LEO Pharma and is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, Eli Lilly and Company, Celgene, and Novartis. This research was performed independently through the authors' academic university affiliations. Pfizer, Eli Lilly and Company, Novo Nordisk, and LEO Pharma had no influence on data collection, no access to the data, and no influence on the decision to submit. |
Vol 73 - N° 5
P. 829-835 - novembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?